Advaxis rallies on licensing deal for ADXS-HPV

Advaxis (ADXS +11.1%) rises after saying it has entered into a licensing agreement with Global BioPharma for the development and commercialization of ADXS-HPV.

Global BioPharma was formed "solely to focus on the development and commercialization of ADXS-HPV," ADXS says.

ADXS will receive "event-based financial milestones, an annual development fee, and annual net sales royalty payments in the high single to double digits."

Additionally, Global will make an upfront investment in ADXS common stock.

For more on the deal, see here.

Comments (1)
  • NJ shadow
    , contributor
    Comments (9) | Send Message
    given the string of good news in 2013 and several favorable Seeking Alpha articles Advaxis is greatly undervalued
    9 Dec 2013, 02:51 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs